Cargando…

Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy

The integrated stress response (ISR) converges on eIF2α phosphorylation to regulate protein synthesis. ISR is activated by several stress conditions, including endoplasmic reticulum (ER) stress, executed by protein kinase R-like endoplasmic reticulum kinase (PERK). We report that ER stress combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahameed, Mohamed, Boukeileh, Shatha, Obiedat, Akram, Darawshi, Odai, Dipta, Priya, Rimon, Amit, McLennan, Gordon, Fassler, Rosi, Reichmann, Dana, Karni, Rotem, Preisinger, Christian, Wilhelm, Thomas, Huber, Michael, Tirosh, Boaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066181/
https://www.ncbi.nlm.nih.gov/pubmed/32161259
http://dx.doi.org/10.1038/s41467-020-15067-5
_version_ 1783505193581674496
author Mahameed, Mohamed
Boukeileh, Shatha
Obiedat, Akram
Darawshi, Odai
Dipta, Priya
Rimon, Amit
McLennan, Gordon
Fassler, Rosi
Reichmann, Dana
Karni, Rotem
Preisinger, Christian
Wilhelm, Thomas
Huber, Michael
Tirosh, Boaz
author_facet Mahameed, Mohamed
Boukeileh, Shatha
Obiedat, Akram
Darawshi, Odai
Dipta, Priya
Rimon, Amit
McLennan, Gordon
Fassler, Rosi
Reichmann, Dana
Karni, Rotem
Preisinger, Christian
Wilhelm, Thomas
Huber, Michael
Tirosh, Boaz
author_sort Mahameed, Mohamed
collection PubMed
description The integrated stress response (ISR) converges on eIF2α phosphorylation to regulate protein synthesis. ISR is activated by several stress conditions, including endoplasmic reticulum (ER) stress, executed by protein kinase R-like endoplasmic reticulum kinase (PERK). We report that ER stress combined with ISR inhibition causes an impaired maturation of several tyrosine kinase receptors (RTKs), consistent with a partial block of their trafficking from the ER to the Golgi. Other proteins mature or are secreted normally, indicating selective retention in the ER (sERr). sERr is relieved upon protein synthesis attenuation and is accompanied by the generation of large mixed disulfide bonded complexes, including ERp44. sERr was pharmacologically recapitulated by combining the HIV-protease inhibitor nelfinavir with ISRIB, an experimental drug that inhibits ISR. Nelfinavir/ISRIB combination is highly effective to inhibit the growth of RTK-addicted cell lines and hepatocellular (HCC) cells in vitro and in vivo. Thus, pharmacological sERr can be utilized as a modality for cancer treatment.
format Online
Article
Text
id pubmed-7066181
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-70661812020-03-18 Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy Mahameed, Mohamed Boukeileh, Shatha Obiedat, Akram Darawshi, Odai Dipta, Priya Rimon, Amit McLennan, Gordon Fassler, Rosi Reichmann, Dana Karni, Rotem Preisinger, Christian Wilhelm, Thomas Huber, Michael Tirosh, Boaz Nat Commun Article The integrated stress response (ISR) converges on eIF2α phosphorylation to regulate protein synthesis. ISR is activated by several stress conditions, including endoplasmic reticulum (ER) stress, executed by protein kinase R-like endoplasmic reticulum kinase (PERK). We report that ER stress combined with ISR inhibition causes an impaired maturation of several tyrosine kinase receptors (RTKs), consistent with a partial block of their trafficking from the ER to the Golgi. Other proteins mature or are secreted normally, indicating selective retention in the ER (sERr). sERr is relieved upon protein synthesis attenuation and is accompanied by the generation of large mixed disulfide bonded complexes, including ERp44. sERr was pharmacologically recapitulated by combining the HIV-protease inhibitor nelfinavir with ISRIB, an experimental drug that inhibits ISR. Nelfinavir/ISRIB combination is highly effective to inhibit the growth of RTK-addicted cell lines and hepatocellular (HCC) cells in vitro and in vivo. Thus, pharmacological sERr can be utilized as a modality for cancer treatment. Nature Publishing Group UK 2020-03-11 /pmc/articles/PMC7066181/ /pubmed/32161259 http://dx.doi.org/10.1038/s41467-020-15067-5 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Mahameed, Mohamed
Boukeileh, Shatha
Obiedat, Akram
Darawshi, Odai
Dipta, Priya
Rimon, Amit
McLennan, Gordon
Fassler, Rosi
Reichmann, Dana
Karni, Rotem
Preisinger, Christian
Wilhelm, Thomas
Huber, Michael
Tirosh, Boaz
Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy
title Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy
title_full Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy
title_fullStr Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy
title_full_unstemmed Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy
title_short Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy
title_sort pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066181/
https://www.ncbi.nlm.nih.gov/pubmed/32161259
http://dx.doi.org/10.1038/s41467-020-15067-5
work_keys_str_mv AT mahameedmohamed pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT boukeilehshatha pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT obiedatakram pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT darawshiodai pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT diptapriya pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT rimonamit pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT mclennangordon pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT fasslerrosi pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT reichmanndana pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT karnirotem pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT preisingerchristian pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT wilhelmthomas pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT hubermichael pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy
AT tiroshboaz pharmacologicalinductionofselectiveendoplasmicreticulumretentionasastrategyforcancertherapy